# Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

> **NCT02744092** · NA · COMPLETED · sponsor: **Alliance Foundation Trials, LLC.** · enrollment: 811 (actual)

## Conditions studied

- Cancer
- Venous Thromboembolism
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Blood Clot

## Interventions

- **DRUG:** Rivaroxaban
- **DRUG:** Apixaban
- **DRUG:** Edoxaban
- **DRUG:** Dabigatran
- **DRUG:** Warfarin
- **DRUG:** Dalteparin
- **DRUG:** Enoxaparin
- **DRUG:** Fondaparinux

## Key facts

- **NCT ID:** NCT02744092
- **Lead sponsor:** Alliance Foundation Trials, LLC.
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-13
- **Primary completion:** 2020-10-31
- **Final completion:** 2021-02-22
- **Target enrollment:** 811 (ACTUAL)
- **Last updated:** 2023-10-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02744092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02744092, "Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02744092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*